These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37248971)

  • 1. Economic and cost-effectiveness aspects of vaccines in combating antibiotic resistance.
    Yemeke T; Chen HH; Ozawa S
    Hum Vaccin Immunother; 2023 Dec; 19(1):2215149. PubMed ID: 37248971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): Case study using DREAMR in Ethiopia.
    Ozawa S; Chen HH; Rao GG; Eguale T; Stringer A
    Vaccine; 2021 Oct; 39(45):6700-6711. PubMed ID: 34538697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health and economic impact of the pneumococcal conjugate vaccine in hindering antimicrobial resistance in China.
    Lu EY; Chen HH; Zhao H; Ozawa S
    Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33758096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR.
    Sevilla JP; Bloom DE; Cadarette D; Jit M; Lipsitch M
    Proc Natl Acad Sci U S A; 2018 Dec; 115(51):12911-12919. PubMed ID: 30559203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting antimicrobial resistance in Streptococcus pneumoniae following vaccination introduction.
    Watkins ER; Kalizang'Oma A; Gori A; Gupta S; Heyderman RS
    Trends Microbiol; 2022 Dec; 30(12):1135-1145. PubMed ID: 35843855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.
    Boonacker CW; Broos PH; Sanders EA; Schilder AG; Rovers MM
    Pharmacoeconomics; 2011 Mar; 29(3):199-211. PubMed ID: 21250759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination to Reduce Antimicrobial Resistance Burden-Data Gaps and Future Research.
    Tadesse BT; Keddy KH; Rickett NY; Zhusupbekova A; Poudyal N; Lawley T; Osman M; Dougan G; Kim JH; Lee JS; Jeon HJ; Marks F
    Clin Infect Dis; 2023 Dec; 77(Suppl 7):S597-S607. PubMed ID: 38118013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use.
    Shrestha P; Cooper BS; Coast J; Oppong R; Do Thi Thuy N; Phodha T; Celhay O; Guerin PJ; Wertheim H; Lubell Y
    Antimicrob Resist Infect Control; 2018; 7():98. PubMed ID: 30116525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions.
    Shiri T; Khan K; Keaney K; Mukherjee G; McCarthy ND; Petrou S
    Value Health; 2019 Nov; 22(11):1329-1344. PubMed ID: 31708071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Antibiotic Resistance on Treatment of Pneumococcal Disease in Ethiopia: An Agent-Based Modeling Simulation.
    Chen HH; Stringer A; Eguale T; Rao GG; Ozawa S
    Am J Trop Med Hyg; 2019 Nov; 101(5):1042-1053. PubMed ID: 31516111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
    Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
    Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review.
    Tin Tin Htar M; van Den Biggelaar AHJ; Sings H; Ferreira G; Moffatt M; Hall-Murray C; Verstraeten T; Gessner BD; Schmitt HJ; Jodar L
    Expert Rev Vaccines; 2019 Oct; 18(10):1069-1089. PubMed ID: 31585049
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk modelling the mortality impact of antimicrobial resistance in secondary pneumococcal pneumonia infections during the 2009 influenza pandemic.
    Barnes CE; MacIntyre CR
    Int J Infect Dis; 2019 Aug; 85():1-6. PubMed ID: 31096052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of vaccines in fighting antimicrobial resistance (AMR).
    Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2018; 14(9):2142-2149. PubMed ID: 29787323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CIRCULATING CLONAL COMPLEXES AND SEQUENCE TYPES OF STREPTOCOCCUS PNEUMONIAE SEROTYPE 19A WORLDWIDE: THE IMPORTANCE OF MULTIDRUG RESISTANCE: A SYSTEMATIC LITERATURE REVIEW.
    Ruiz García Y; Nieto Guevara J; Izurieta P; Vojtek I; Ortega-Barría E; Guzman-Holst A
    Expert Rev Vaccines; 2021 Jan; 20(1):45-57. PubMed ID: 33507135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness.
    Wilton P; Smith R; Coast J; Millar M
    J Health Serv Res Policy; 2002 Apr; 7(2):111-7. PubMed ID: 11934376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands.
    Bos JM; Rümke H; Welte R; Postma MJ
    Clin Ther; 2003 Oct; 25(10):2614-30. PubMed ID: 14667962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
    Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
    Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.